Chardan Capital Maintains Buy on Avidity Biosciences, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Keay Nakae maintains a Buy rating on Avidity Biosciences (NASDAQ:RNA) and raises the price target from $33 to $45.
June 12, 2024 | 6:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has reaffirmed its Buy rating on Avidity Biosciences and increased the price target from $33 to $45, indicating strong confidence in the company's future performance.
The increase in the price target from $33 to $45 by Chardan Capital suggests a positive outlook for Avidity Biosciences. This is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100